Zuellig Pharma


Zuellig Pharma
Full Prescribing Info
Fluorouracil, salicylic acid, dimethylsufoxide.
100 g solution contain: fluorouracil 0.5 g; salicylic acid 10.0 g; dimethylsulfoxide 8.0 g.
Verrumal is a therapeutic for use in warts with a unique combination of active ingredients. It has been shown that the combined action of fluorouracil and salicylic acid is of particular advantage in the treatment of warts.
Fluorouracil takes effect against the pathologically increased cell growth in warts.
Salicylic acid softens and dissolves the horny material of warts and as a result it promotes penetration of the active ingredients at the same time. Dimethylsulfoxide serves as a solubilizer for the active ingredient fluorouracil.
A film-forming solution has been chosen as solvent base to promote penetration of the active ingredients into the warts.
After application to the skin Verrumal forms a firm whitish film after the solvent has evaporated.
Common warts, flat juvenile warts and plantar warts.
Dosage/Direction for Use
Unless otherwise directed by the physician, Verrumal is applied 2-3 times daily to every wart. Verrumal may only be applied to the wart and not to the surrounding healthy skin.
It is advisable to remove excessive solution from the brush on the neck of the bottle before painting the warts. Very small warts can be painted using a wooden tooth-pick, etc, instead of the brush for more exact application. Prior to each renewed application of Verrumal the existing lacquer film should be removed by stripping.
In warts round or under the nails (periungual or subungual warts) care should be taken that Verrumal is not applied to the nail bed.
The size of the treated area should not exceed 25 cm2.
During treatment it is recommended to consult the physician at regular intervals. Empirically, it is of advantage in some cases for the physician to remove the necrotic tissue resulting from treatment with Verrumal.
The average duration of treatment is 6 weeks.
Treatment should be continued for a further week or so after successful therapy.
Verrumal should not be used in the lactation period, in pregnant women or in women in whom pregnancy cannot be reliably excluded.
Furthermore, it should not be used in persons hypersensitive to the preparation.
Verrumal should not be used in babies.
Verrumal is not intended for use on large skin areas (skin area larger than 25 cm2).
Verumal may not come into contact with the eyes or mucous membranes.
Side Effects
Occasional burning, particularly after application.
Erosive cutaneous reactions in rare cases.
Marked burning may necessitate discontinuation of therapy in very isolated cases. Owing to the intensive softening effect on the horny layer, whitish discoloration and desquamation of the skin can occur particularly in the vicinity of the warts.
Caution For Usage
The bottle should be tightly closed after use since the preparation rapidly evaporates if the bottle is open and the solution can no longer be used according to instructions.
Store between (15 - 25°C).
Patient Counseling Information
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
The doctor and the pharmacist are the experts in medicines, their benefits and risks.
Do not by yourself interrupt the period of treatment prescribed.
Do not repeat the same prescription without consulting your doctor.
ATC Classification
D11AF - Wart and anti-corn preparations ; Used in the treatment of warts and corns.
Topical soln 13 mL.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in